MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
0.6501
-0.0289
-4.26%
Opening 12:29 10/09 EDT
OPEN
0.6410
PREV CLOSE
0.6790
HIGH
0.6799
LOW
0.6353
VOLUME
156.91K
TURNOVER
--
52 WEEK HIGH
8.49
52 WEEK LOW
0.6042
MARKET CAP
15.61M
P/E (TTM)
-0.7311
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2d ago
Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Actuate Therapeutics' Stock Tumble on Plan to Sell 50M Shares
Dow Jones · 2d ago
*Actuate Therapeutics to Issue 3.7M Warrants to Bios Partners and Kairos Venture Investments in Connection With Agreements Not to Sell Shares for Two Years After Stock Sale Closes
Dow Jones · 2d ago
*Actuate Therapeutics Files to Sell 50M Shrs
Dow Jones · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 2d ago
Actuate Therapeutics To Sell 50,000,000 Shares At Assumed Price Of $0.819 Per Share
Benzinga · 2d ago
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.